Efficacy of daratumumab in refractory primary Sjögren disease

RMD Open. 2023 Sep;9(3):e003464. doi: 10.1136/rmdopen-2023-003464.

Authors

Gaetane Nocturne^{1

2}, Oriane Marmontel^{3

4}, Mathilde di Filippo^{3

4}, Pascale Chretien⁵, Roman Krzysiek⁵, Francois Lifermann⁶, Nawal Rahal¹, Rakiba Belkhir¹, Philippe Moulin^{3

4}, Xavier Mariette^{7

2}

Affiliations

¹ Rheumatology Department, Hôpital Bicêtre, Le Kremlin-Bicetre, France.
² INSERM UMR 1184, Le Kremlin-Bicêtre, France.
³ Service de Biochimie et Biologie moléculaire, Laboratoire de Biologie Médicale Multi-sites, Hospices Civils de Lyon, F-69677, Lyon Cedex, France, Lyon, France.
⁴ CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.
⁵ Laboratoire d'Immunologie, Hopital Bicetre, Le Kremlin-Bicetre, France.
⁶ Service de médecine interne, CH de Dax, Dax, France.
⁷ Rheumatology Department, Hôpital Bicêtre, Le Kremlin-Bicetre, France xavier.mariette@aphp.fr.

No abstract available

Keywords: Autoimmune Diseases; Biological Therapy; Sjogren's Syndrome.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Humans
Sjogren's Syndrome* / drug therapy

Substances

Antibodies, Monoclonal
daratumumab